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locations, while further away principal stresses predominate. Increased neointimal
thickness seems to relate to increased von Mises stresses at the site of stent struts.
Evaluating induced tissue stresses with stent-artery interaction models may improve
future device designs.
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Background: The safety and effectiveness of XIENCE V® everolimus-eluting stents
(XIENCE V, Abbott Vascular, Santa Clara, CA) at 1 year (1Y) in real world clinical
settings have been demonstrated in XIENCE V USA trial with low rates of target lesion
revascularization (TLR), cardiac death, MI and stent thrombosis (ST). Data on whether
these results are maintained through longer follow-up have not yet been reported.
Methods: XIENCE V USA is a prospective, multicenter, single-arm, FDA required
condition of approval study designed to examine the safety and effectiveness of
XIENCE V in an all-inclusive, consecutively-enrolled population from real world
clinical settings. Clinical endpoint events, including ST, cardiac death, MI, and
revascularization were adjudicated by an independent Clinical Events Committee.
Results: A total of 4382 patients completed 2-year (2Y) follow up. Baseline
Characteristics and Clinical Outcomes through 2Y appear in the table below.
Baseline Characteristics and Clinical Outcomes through 2 Years
1ARC MI definition: elevation of troponin or CKMB > 3 URL for periprocedual
PCI, > 5 URL for periprocedual CABG, and > 1 URL for spontaneous MI                   
2WHO MI definition: QMI per ECG or elevation of CK ≥ 2 URL with elevated
CKMB in the absence of new pathological Q waves              
3TLF: composite of cardiac death, MI attributed to target vessel, and clinically-
indicated TLR
Conclusion: Low event rates observed at 1Y were maintained through 2Y. Of note,
despite the increased number of patients who discontinued DAPT by 2 Y, the ST rate
remained consistently low, and <1% at 2Y. These results demonstrate continued safety
and effectiveness of the XIENCE V in a highly complex, real world patient population
through 2Y.
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Background: The purpose of the STEALTH I trial was to assess the safety and efficacy
of the Biolimus A9™-eluting stent with a biodegradable polymer coating
(BioMatrix™), as compared to a bare metal control stent (S-Stent™). The purpose of
this presentation is to present the 5 year and final report of this study.
Methods: This is a prospective, randomized, double-blind study which enrolled
patients in 3 centers in Germany (2) and Brazil. A total of 120 patients were enrolled
and randomly allocated 2:1 to receive the BioMatrix stent (BES) or the S-Stent (BMS).
The primary endpoint was in-stent late loss at 6 months. Secondary endpoints include
MACE defined as a composite of death, myocardial infarction, and target lesion
revascularization at 30 days, 3, 6 months, 1 year and then yearly up to 5 years.
Angiographic follow-up (measured by QCA) was protocol mandated at 6 months.
IVUS was performed immediately post-procedure and at 6 months.
Results: The mean age for BES patients was 62.2 ±10 years, 60.0% were male; 26.6%
had a history of diabetes mellitus. The in-stent late loss at 6 months was 0.19 mm ±
0.39 mm for BES patients compared to 0.76 mm (± 0.45 mm) for BMS patients (
p<0.001). In-segment late loss was 0.09 ± 0.31 (BES) vs. 0.48 ± 0.43 (BMS), p<0.001.
Out to 5 years a MACE event occurred in 13 patients (18.1%) for BES compared to 4
patients (10.5%) treated with a BMS (p =0.41). There was 1 acute and one late stent
thrombosis (protocol-defined) in the BES group.
Conclusion: The BioMatrix stent demonstrated statistical superiority for both in-
segment and in-stent late loss at 6 months compared to the bare metal control stent.
This benefit was achieved without an increase in adverse safety outcomes assessed.
The long-term clinical results demonstrate that the BioMatrix stent maintains an
adequate safety profile equal with conventional bare metal stents.
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Background: Information is lacking regarding prasugrel use following TAXUS Liberte
stent implantation in routine clinical practice.
Methods: The TAXUS Liberte Post-Approval Study is a prospective, multicenter
registry that will examine 5-year clinical outcomes in patients with implanted TAXUS
Liberte stents with concomitant prasugrel therapy. Enrollment of approximately 4200
total patients at up to 100 sites is planned. Following an initial enrollment of 3600
planned “real world” patients, an additional 600 patients with restricted eligibility
criteria will be enrolled. Once stented, patients will be prescribed aspirin and prasugrel
(at 5 mg or 10 mg doses, as appropriate) for 12 months, followed by 1:1 randomization
to either continued prasugrel or placebo for an additional 18 months. This presentation
will evaluate the in-hospital experience of the “real-world” patient cohort. Where
appropriate, comparisons will be made to the TAXUS ARRIVE registry, which enrolled
7492 “real world” patients receiving the previous generation TAXUS Express-2 stent
between 2004 and 2005.
Results: Enrollment of approximately 3600 “real world” patients was completed in
March 2011 and data are currently being analyzed. The presentation will include: (1)
patient demographics and procedural characteristics, compared across the TAXUS
Liberte and TAXUS ARRIVE registries; (2) data regarding prasugrel dose and usage
rates, including drug switching, in the TAXUS Liberte registry; (3) in-hospital major
adverse cardiac events (MACE; defined as cardiac death, myocardial infarction, and
target vessel revascularization) and stent thrombosis in the TAXUS Liberte registry
compared to TAXUS ARRIVE; and (4) cerebrovascular event rates and bleeding
(defined per GUSTO criteria) in the TAXUS Liberte registry.
Conclusion: The TAXUS Liberte Post-Approval Study will be the first to assess
prasugrel use in “real world” patients receiving the TAXUS Liberté stent. This abstract
will present the initial experience of this study, including in-hospital MACE,
cerebrovascular events, and bleeding data.
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Background: The sirolimus-eluting stent (SES) has reduced the rate of restenosis
compared to use of the bare-metal stent for longer stented segments. The object of the
study was to examine the relationships of total stent length (TSL) per patient and per
lesion with target lesion revascularization (TLR) and stent thrombosis (ST) at 5 years.
Methods: The j-Cypher Registry includes consecutive patients receiving a SES in 37
centers in Japan. By February 2011, 5-year follow-up data were available for 10,773
patients and 17,040 lesions with exclusively SES implantation. The patients and lesions
were divided into four groups according to quartiles for TSL per patient or per lesion:
Q1: TSL-P 8-18 mm, N=2,819; Q2: TSL-P 19-28 mm, N=2,570; Q3: TSL-P 28-51
mm, N=2,929; Q4: TSL-P 52-293 mm, N=2,455; QA: TSL-L 8-18 mm, N=6,167; QB:
TSL-L 19-23 mm, N=4,040; QC: TSL-L 23-33 mm, N=2,790; QD: TSL-L 33-150 mm,
N=4,043.
Results: The 5-year TLR rates were 8.8% in Q1, 9.8% in Q2, 14.1% in Q3 and 22.2%
in Q4 (p<0.0001); and 8.4% in QA, 9.1% in QB, 10.8% in QC and 17.4% in QD
(p<0.0001). The 5-year definite/probable ST per patient rates were 1.24% in Q1, 1.28%
in Q2, 1.88% in Q3 and 2.32% in Q4 (p<0.023); and definite stent thrombosis per
lesion rates were 0.88% in QA, 0.79% in QB, 1.00% in QC and 1.41% in QD
(p=0.0228).
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